Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.59 |
| ▸ | FYN | P06241 | 6/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17004641 | 0.77 | KCNH2 (0.51) | KCNH2FYNMAP4K4CHEK2TGFBR1 | |
| SCHEMBL13837104 | 0.74 | KCNH2 (1.00) | KCNH2FYNMAP4K4CHEK2TGFBR1 | |
| SCHEMBL12517982 | 0.73 | KCNH2 (1.00) | KCNH2FYN | |
| SCHEMBL2226033 | 0.73 | FYN (0.76) | KCNH2FYNMAP4K4CHEK2TGFBR1 | |
| SCHEMBL12516844 | 0.72 | KCNH2 (0.77) | KCNH2FYNMAP4K4CHEK2 | |
| SCHEMBL13837178 | 0.71 | KCNH2 (0.70) | KCNH2FYNMAP4K4CHEK2TGFBR1 | |
| SCHEMBL27902100 | 0.71 | KCNH2 (0.70) | KCNH2FYNMAP4K4CHEK2TGFBR1 | |
| SCHEMBL28775974 | 0.70 | KDM4E (0.39) | — | |
| SCHEMBL18394286 | 0.69 | PDE4B (0.37) | — | |
| Methylpiperazine SCHEMBL17004635 | 0.69 | KCNH2 (0.71) | KCNH2FYNTGFBR1ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2526090-B1 | NEW ANTI-MALARIAL AGENTS | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2015-08-19 | — | — | EP | claimed |
| US-20120295905-A1 | NEW ANTI-MALARIAL AGENTS | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2012-11-22 | — | — | US | claimed |
| US-9024033-B2 | Anti-malarial agents | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2015-05-05 | — | — | US | disclosed |
| US-20120295905-A1 | NEW ANTI-MALARIAL AGENTS | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295905-A1 | NEW ANTI-MALARIAL AGENTS | QDPR, DHFR, ITPA | KCNH2 1101/4885FYN 3839/4885KDM1A 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.